WHITELEY v. ZYNERBA PHARMACEUTICALS, INC.

CourtDistrict Court, E.D. Pennsylvania
DecidedSeptember 16, 2021
Docket2:19-cv-04959
StatusUnknown

This text of WHITELEY v. ZYNERBA PHARMACEUTICALS, INC. (WHITELEY v. ZYNERBA PHARMACEUTICALS, INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
WHITELEY v. ZYNERBA PHARMACEUTICALS, INC., (E.D. Pa. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

SCOTT WHITELEY and HARRY : CIVIL ACTION BERER, individually and on behalf of : all others similarly situated, : NO. 19-4959 Plaintiffs : : v. : : ZYNERBA PHARMACEUTICALS, : INC., et al., : Defendants :

SEPTEMBER 16, 2021

MEMORANDUM OPINION INTRODUCTION Before this Court is a motion for final approval of class action settlement and final determination that class certification for settlement purposes is appropriate, [ECF 45], and a motion for an award of attorneys’ fees, reimbursement of expenses, and compensatory awards to lead plaintiffs, [ECF 46], both filed by Plaintiffs Scott Whiteley and Harry Berger pursuant to Federal Rule of Civil Procedure (“Rule”) 23. Previously, this Court granted preliminary approval to the underlying class action settlement agreement (the “Settlement Agreement”). [ECF 44]. A hearing was held on August 31, 2021 (the “Fairness Hearing”), at which the Court heard oral argument on Plaintiffs’ unopposed motion for final approval of the Settlement Agreement. Counsel for all parties appeared. For the reasons stated herein, the motion for final approval of the class action settlement and motion for attorneys’ fees and expenses are both granted.

BACKGROUND Plaintiffs Scott Whiteley and Harry Berger, on behalf of themselves and all others similarly situated, brought this class action against Defendants Zynerba Pharmaceuticals, Inc. (“Zynerba), Armando Anido, and James E. Fickenscher (collectively, “Defendants”), asserting various claims for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act, 15 U.S.C. §§

78j(b), and 78t(a), and Rule 10b-5 promulgated thereunder by the Securities and Exchange Commission. Specifically, Plaintiffs alleged that during the Settlement Class Period, Zynerba conducted Phase II clinical testing of Zygel to assess its efficacy and safety for treatment of child and adolescent patients with developmental and epileptic encephalopathies via a clinical trial called the “BELIEVE 1” trial. Zygel is a transdermal cannabinoid-based treatment, and Zynerba’s only product in development. In the amended complaint, Plaintiffs alleged that Defendants knew about but failed to timely disclose adverse events experienced by participants during the BELIEVE 1 trial. When this material information was reported on September 18, 2019, Zynerba’s stock price fell $2.46 per share (21.77%). From the outset of this litigation, Defendants have denied any wrongdoing and vigorously

defended this action. Initially, Defendants filed a motion to dismiss, which this Court granted, in part, and denied, in part. Defendants filed a motion for reconsideration, which this Court denied. After Defendants file an answer to the amended complaint, the parties participated in a full-day mediation with a private mediator. The parties reached an agreement in principle, which was eventually memorialized in a settlement agreement on April 30, 2021.

The Terms of the Settlement The Settlement, the full terms of which are set forth in the Settlement Agreement, provides substantial economic benefits to the certified class (the “Class”).1 The Settlement creates a total settlement fund of $4.0 million (the “Settlement Fund”), to be reduced by any amount approved by this Court for attorneys’ fees and costs, and for the class representative service awards.

Preliminary Approval and Class Notice

By Order dated May 12, 2021, this Court granted preliminary approval to the proposed Settlement and provisionally certified the proposed class. Pursuant to this Court’s Preliminary Approval Order, Strategic Claims Services (“SCS”) was appointed to serve as the Settlement Administrator. As part of its responsibilities, SCS sent notice to the relevant governmental officials under the Class Action Fairness Act (“CAFA”), 28 U.S.C. §1715, et seq., effected publication notice, and sent direct notice to Class Members in accordance with the plan for notice, which this Court found to be the best notice practicable under the circumstances and consistent with the requirements of due process. SCS mailed notices to thirty-seven (37) individuals and organizations identified in the transfer agent records. SCS also mailed a letter to 1,224 nominees contained in its proprietary master mailing list, which notified the recipients of the settlement and requested that within ten (10) calendar days that they either: (a) send a postcard notice to their customers who may be beneficial purchasers/owners; (b) email either an electronic version of the Summary Notice of Pendency and Proposed Settlement of Action and Final Approval Hearing (“Publication Notice”) or a direct link to the Notice of Proposed Settlement of Class Action, Motion for Attorneys’ Fees and Expenses, and Settlement Fairness Hearing (“Long Notice”) and Proof of Claim and Release Form (“Claim Form”) supplied by SCS to their beneficial purchasers/owners; or (c) provide SCS with a list of the names, mailing addresses, and email

1 Unless otherwise defined herein, all capitalized terms shall have the meanings provided in the Settlement Agreement. addresses, to the extent email addresses were available, of such beneficial owners so that SCS could promptly mail the Postcard Notice or email the links to the Long Notice and Claim Form directly to them. As a result of this notice procedure, SCS mailed 24,807 Postcard Notices. In addition, Certain Nominee Account Holders notified SCS that they collectively emailed 15,805

potential Settlement Class Members to notify them of the Settlement and provide either the Publication notice or direct links to the Long Notice and Claim form on the Settlement webpage. SCS also sent the Depository Trust Company a Long Notice and Claim Form to post on its Legal Notice system and arranged for the Publication Notice to be published electronically once on the GlobeNewswire and in print in the Investor’s Business Daily. The deadline for filing objections and requests for exclusion was August 10, 2021. As of the date of the Fairness Hearing, there were no objections, and only two (one invalid) requests for exclusion.

DISCUSSION When granting final approval of a class action settlement, a district court must hold a hearing and conclude that the proposed settlement is fair, reasonable, and adequate. See Fed. R. Civ. P. 23(e)(2); Sullivan v. DB Invs., Inc., 667 F.3d 273, 295 (3d Cir. 2011); In re Ins. Brokerage Antitrust Litig., 579 F.3d 241, 258 (3d Cir. 2009). Although there is a strong judicial policy in favor of voluntary settlement agreements, Pennwalt Corp. v. Plough, 676 F.2d 77, 79-80 (3d Cir. 1982), courts are generally afforded broad discretion in determining whether to approve a proposed

class action settlement. Eichenholtz v. Brennan, 52 F.3d 478, 482 (3d Cir. 1995). “The law favors settlement particularly in class actions and other complex cases where substantial judicial resources can be conserved by avoiding formal litigation.” In re Gen. Motors Corp. Pick-Up Truck Fuel Tank Prod. Liab., 55 F.3d 768, 784 (3d Cir. 1995). In addition to conservation of judicial resources, “[t]he parties may also gain significantly from avoiding the costs and risks of a lengthy and complex trial.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
In Re Pet Food Products Liability Litigation
629 F.3d 333 (Third Circuit, 2010)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
Pennwalt Corporation v. Plough, Inc.
676 F.2d 77 (Third Circuit, 1982)
Baby Neal v. Casey
43 F.3d 48 (Third Circuit, 1994)
In Re: Cendant Corporation Prides Litigation
243 F.3d 722 (Third Circuit, 2001)
Edwin Maldonado v. Feather O. Houstoun
256 F.3d 181 (Third Circuit, 2001)
In Re: Cendant Corporation Litigation
264 F.3d 201 (Third Circuit, 1992)
Robert Stewart v. Lynne Abraham
275 F.3d 220 (Third Circuit, 2001)
Dewey v. Volkswagen Aktiengesellschaft
681 F.3d 170 (Third Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
WHITELEY v. ZYNERBA PHARMACEUTICALS, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/whiteley-v-zynerba-pharmaceuticals-inc-paed-2021.